Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.
2 reports, 2 independent
Updated Jun 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
-
Morgan Stanley
U.S. investment bank
Related events
- Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.
- Viking Therapeutics, Nasdaq, and Meta are involved in a market update regarding shared growth in growth sectors.
- Analyst provides a high price target for Viking Therapeutics stock.